ALNY Prices Offering At $95/Share

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) has offered to sell 4.74 million shares of its common stock to the public at a price of $95 each. The offering, which is expected to bring in aggregate proceeds of approximately $450 million, is scheduled to close on or about January 26, 2015.

The company has a couple of events lined up for this year.

- Data from an on-going phase II open-label extension study with Patisiran in patients with familial amyloidotic polyneuropathy are scheduled to be reported by mid-2015.

- Data from an on-going phase II OLE study with Revusiran in patients with TTR cardiac amyloidosis are expected to be available this year.

- Additional results from an on-going phase I study of ALN-AT3 for the treatment of hemophilia and rare bleeding disorders are anticipated in mid-2015, and complete data in late 2015.

- A phase 1/2 study of ALN-CC5 for the treatment of complement-mediated diseases is scheduled to be initiated in early 2015. Initial data from this trial are expected in mid-2015 and additional data in late 2015.

By the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs - including 4 in late stages of development - across 3 Strategic Therapeutic Areas.

ALNY closed Tuesday's trading at $96.25, down 4.49%.